one
aim
hiv
vaccin
elicit
neutral
antibodi
nab
limit
replic
genet
divers
virus
prevent
establish
new
infect
thu
identifi
strength
weak
nab
earli
stage
natur
infect
could
prove
use
achiev
goal
demonstr
viral
escap
readili
occur
despit
develop
high
titer
autolog
nab
two
subject
acuteearli
subtyp
c
infect
provid
detail
portray
escap
pathway
nab
resist
variant
identifi
multipl
time
point
use
creat
seri
envelop
env
glycoprotein
chimera
mutant
within
background
correspond
newli
transmit
env
one
subject
nab
escap
driven
predominantli
chang
region
extend
begin
domain
end
domain
howev
nab
escap
pathway
subject
oscil
time
requir
cooper
ectodomain
second
subject
escap
driven
chang
escap
pathway
retain
time
util
reflect
viru
abil
escap
two
distinct
monoclon
antibodi
mab
deriv
patient
via
introduct
singl
potenti
nlink
glycosyl
site
spatial
represent
sequenc
chang
suggest
select
pressur
act
upon
region
env
two
subject
even
though
env
domain
drove
escap
differ
togeth
find
argu
singl
mutat
pathway
suffici
confer
escap
earli
subtyp
c
infect
support
model
multipl
strategi
includ
potenti
glycan
shift
direct
alter
epitop
sequenc
cooper
env
domain
conform
mask
use
evad
neutral
current
aid
pandem
result
genet
divers
viral
subtyp
circul
recombin
form
crf
group
subtyp
c
account
major
infect
worldwid
key
sourc
genet
divers
viral
env
gene
encod
envelop
env
glycoprotein
review
virion
monom
noncoval
associ
subunit
trimer
form
spike
togeth
facilit
entri
target
cell
env
complex
conform
undergo
substanti
rearrang
subunit
upon
bind
coreceptor
env
also
contain
princip
target
neutral
antibodi
nab
epitop
target
env
subunit
howev
mani
potenti
neutral
target
transient
expos
trimer
form
virionassoci
env
includ
domain
epitop
bind
site
despit
limit
infect
patient
develop
robust
nab
respons
autolog
viru
particularli
infect
subtyp
c
confer
potent
broad
neutral
expect
epitop
need
possess
least
four
properti
exposur
virionassoci
nativ
env
trimer
ii
conserv
across
divers
variant
iii
immunogen
iv
lack
autoreact
date
epitop
meet
criteria
howev
knowledg
epitop
recogn
nab
natur
infect
divers
somewhat
limit
known
mani
epitop
target
initi
autolog
nab
respons
proport
epitop
strainspecif
share
antigen
differ
patient
viral
subtyp
predomin
escap
mechan
furthermor
mount
evid
least
paramet
differ
subtyp
review
other
character
autolog
nab
respons
first
develop
observ
high
titer
autolog
nab
activ
infect
strain
patient
addit
report
higher
nab
titer
subtyp
c
infect
patient
compar
subtyp
b
infect
patient
evalu
parallel
prompt
group
other
propos
differ
antigen
subtyp
b
c
env
recent
studi
hone
region
could
involv
earli
subtyp
c
autolog
nab
respons
includ
hypervari
domain
subregion
howev
region
could
account
nab
activ
present
patient
plasma
suggest
involv
addit
determin
furthermor
demonstr
independ
pathway
util
escap
nab
chronic
subtyp
c
infect
addit
shown
strong
associ
mutat
helix
region
neutral
resist
although
mutat
directli
alter
neutral
sensit
transfer
sensit
resist
env
link
transmiss
partner
tempor
studi
demonstr
undergo
recurr
cycl
escap
autolog
nab
escap
also
occur
infect
chimer
shiv
viru
respons
vaccineinduc
nab
yet
knowledg
specif
molecular
event
lead
escap
remain
incomplet
shift
carbohydr
moieti
around
outer
surfac
well
chang
hypervari
domain
propos
gener
mechan
use
shiv
alter
neutral
epitop
although
studi
base
subtyp
b
env
nab
escap
shivinfect
macaqu
shown
involv
glycan
chang
domain
perhap
shield
conserv
epitop
bind
site
consist
find
recent
studi
identifi
major
determin
strainspecif
autolog
nab
macaqu
infect
two
differ
strain
shiv
domain
also
shown
princip
determin
inher
nab
resist
strain
jrfl
subtyp
b
also
escap
autolog
nab
shift
nlink
carbohydr
outer
domain
littl
involv
other
demonstr
subtyp
b
viral
escap
could
also
occur
absenc
frank
chang
glycosyl
clear
mutat
pattern
emerg
experiment
sivmac
infect
emerg
nand
olink
carbohydr
hypervari
domain
shown
confer
escap
autolog
neutral
furthermor
presenc
specif
glycan
reduc
immunogen
sivmac
context
experiment
infect
taken
togeth
studi
hint
complex
neutral
escap
also
suggest
common
theme
may
exist
thu
unlik
cytotox
lymphocyt
ctl
epitop
escap
mutat
frequent
predict
associ
viral
sequenc
polymorph
hla
allel
nab
epitop
escap
pathway
env
inher
difficult
identifi
base
sequenc
alon
therefor
undertaken
molecular
approach
defin
subtyp
c
env
earli
infect
use
pseudovirusbas
assay
facilit
evalu
individu
patientderiv
env
analyz
neutral
abil
longitudin
plasma
sampl
contemporaneouslyderiv
autolog
env
two
subtyp
c
seroconvertor
gener
potent
nab
infect
env
sequenti
neutral
escap
variant
emerg
patient
use
env
domain
exchang
sitedirect
mutagenesi
approach
map
pathway
involv
nab
escap
multipl
time
point
throughout
first
two
year
infect
nab
escap
two
patient
driven
independ
pathway
pathway
exhibit
differ
level
stabil
time
yet
spatial
represent
sequenc
chang
indic
immun
pressur
direct
env
region
subject
deriv
autolog
monoclon
antibodi
mab
one
patient
demonstr
singl
potenti
glycan
chang
afford
simultan
resist
multipl
antibodi
studi
therefor
provid
detail
look
nab
escap
subject
recent
infect
predomin
subtyp
worldwid
demonstr
flexibl
env
facilit
use
multipl
mechan
previous
demonstr
subtyp
c
infect
subject
zehrp
cohort
develop
robust
autolog
nab
respons
infect
env
inhibitori
titer
often
exceed
within
first
month
infect
two
subject
develop
potent
autolog
nab
identifi
viral
antigen
posit
tabl
sampl
emerg
quasispeci
singl
genom
pcr
amplif
clone
sequenc
biolog
function
env
gene
longitudin
plasma
pbmc
dna
sampl
subject
env
clone
first
seroposit
time
point
estim
within
day
infect
longitudin
time
calcul
month
signific
obstacl
develop
hiv
vaccin
potenti
viru
escap
immun
respons
induc
immun
previous
show
subject
zambian
cohort
develop
potent
neutral
antibodi
respons
shortli
becom
infect
subtyp
c
extend
find
demonstr
cycl
viral
escap
occur
two
subject
despit
potent
immun
respons
investig
determin
immun
escap
found
singl
common
mutat
pathway
suffici
facilit
viral
escap
instead
demonstr
multipl
strategi
includ
potenti
chang
glycosyl
pattern
direct
alter
epitop
sequenc
cooper
envelop
interact
use
independ
togeth
evad
neutral
also
recov
individu
monoclon
antibodi
one
subject
found
singl
mutat
confer
escap
differ
neutral
antibodi
specif
studi
demonstr
remark
flexibl
subtyp
c
suggest
envelop
glycoprotein
uniqu
equip
adjust
specif
properti
immun
respons
newli
infect
host
point
forward
sampl
five
subsequ
time
point
first
two
year
infect
evalu
subset
env
chosen
repres
divers
circul
quasispeci
time
point
see
arrow
fig
b
evalu
sensit
neutral
contemporan
simultan
collect
plasma
sampl
use
tzmbl
pseudoviru
assay
nab
titer
plasmaenv
combin
calcul
viru
infect
curv
use
growth
function
fig
show
median
titer
env
design
accord
first
seroposit
time
point
see
tabl
higher
contemporan
env
time
point
indic
repeat
cycl
neutral
resist
differ
median
titer
statist
signific
time
point
howev
median
titer
differ
significantli
two
time
point
probabl
due
wide
rang
nab
sensit
observ
contemporan
env
subject
fig
nevertheless
nabresist
variant
present
time
point
neutral
subsequ
plasma
sampl
indic
continu
induct
de
novo
nab
respons
data
shown
gaug
whether
breadth
develop
within
window
evalu
crossneutr
activ
singl
plasma
sampl
subject
subject
measur
heterolog
subtyp
c
env
six
subject
cohort
fig
consist
previou
studi
earli
subtyp
c
infect
nab
mostli
strainspecif
howev
plasma
sampl
neutral
heterolog
env
greater
two
case
approach
interestingli
plasma
potent
neutral
env
red
dot
right
point
plot
reciproc
observ
green
dot
left
point
plot
thu
nab
plasma
sampl
direct
predominantli
strainspecif
target
also
capabl
recogn
common
epitop
approxim
two
year
infect
median
nab
titer
env
significantli
greater
contemporan
env
everi
time
point
use
mannwhitney
test
fig
use
criteria
least
decreas
sensit
neutral
compar
median
env
resist
env
highlight
green
time
point
select
indepth
investig
nab
escap
three
differ
nab
resist
env
select
phylogenet
tree
indic
multipl
lineag
resist
circul
time
point
fig
differ
contemporan
env
reach
signific
two
five
time
point
although
env
time
point
nab
activ
undetect
highest
dilut
plasma
test
fig
env
often
less
sensit
nab
median
env
select
detail
studi
nab
escap
two
genet
divers
env
distinct
lineag
also
select
repres
time
point
fig
next
investig
adapt
respons
escap
contemporan
nab
env
potent
neutral
plasma
subsequ
time
point
fig
b
use
provid
neutral
sensit
background
remain
conserv
amino
acid
level
subsequ
variant
could
use
investig
molecular
determin
escap
nab
resist
variant
two
approach
use
sequenc
chang
limit
nab
resist
env
sitedirect
mutagenesi
use
introduc
potenti
escap
mutat
env
ii
multipl
sequenc
chang
present
nab
resist
env
larger
env
subregion
ie
etc
transfer
nab
resist
env
env
neutral
sensit
chimer
parent
env
evalu
use
plasma
contemporan
nab
resist
env
nab
resist
chosen
determin
sequenc
adapt
respons
earli
nab
escap
fig
demonstr
chimera
contain
either
region
span
loop
end
domain
loop
domain
env
display
level
resist
similar
parent
env
howev
nab
sensit
chimera
contain
entir
domain
unchang
compar
env
despit
chang
fig
therefor
surmis
nab
resist
heavili
depend
upon
subregion
residu
differ
chang
first
posit
helix
two
chang
region
may
also
impact
bind
fig
base
number
none
chang
alter
predict
nlink
glycosyl
site
assess
individu
contribut
nab
resist
amino
acid
chang
introduc
mutat
independ
produc
decreas
neutral
sensit
mutat
combin
recapitul
nab
resist
level
chimera
fig
contrast
chang
helix
decreas
neutral
sensit
introduc
env
fig
togeth
find
indic
combin
mutat
facilit
neutral
resist
month
chang
helix
loop
contribut
detect
level
least
within
context
env
differ
scenario
observ
earli
escap
escap
variant
region
contain
determin
nab
resist
fig
entir
region
differ
amino
acid
fig
two
chang
locat
within
substitut
introduc
potenti
nlink
glycosyl
site
near
ntermin
stem
substitut
number
accord
fig
contrast
introduct
two
chang
decreas
nab
sensit
context
env
fig
third
chang
locat
within
region
potenti
impact
bind
fig
residu
reduc
nab
sensit
fig
thu
complet
nab
resist
could
achiev
sequenc
chang
includ
addit
potenti
nlink
glycan
chang
region
involv
contact
although
mutagenesi
studi
strongli
suggest
chang
nab
escap
mutat
specif
residu
maintain
subsequ
nab
resist
env
fig
howev
sequenc
domain
continu
evolv
time
suggest
ongo
select
pressur
nab
last
time
point
analyz
genet
distinct
lineag
nab
escap
variant
circul
fig
chimeramap
approach
reveal
differ
env
variant
acquir
resist
least
two
distinct
mutat
pathway
fig
see
bottom
panel
detail
map
reveal
domain
continu
contribut
nab
resist
fig
retain
major
escap
pathway
oper
contrast
achiev
similar
level
resist
escap
pathway
requir
ectodomain
addit
cognat
domain
fig
env
region
env
independ
confer
partial
escap
onto
env
insert
ectodomain
alon
effect
nab
sensit
dissect
reveal
somewhat
surprisingli
domain
major
contributor
nab
resist
context
ectodomain
region
context
appear
contribut
escap
thu
cooper
interact
ectodomain
appear
confer
nab
resist
env
nab
escap
primarili
determin
time
found
chang
region
drove
earli
escap
nab
investig
whether
pattern
maintain
time
env
chimera
creat
use
nab
resist
env
five
time
point
followup
period
fig
evalu
use
approach
major
determin
nab
resist
time
point
analyz
see
fig
contrast
region
alon
littl
effect
resist
although
combin
clearli
contribut
escap
effort
precis
defin
nab
target
escap
pathway
b
cell
hybridoma
gener
viabli
frozen
pbmc
sampl
collect
month
infect
earliest
avail
sampl
type
env
clone
use
screen
neutral
activ
hybridoma
supernat
two
hybridoma
produc
monoclon
antibodi
mab
neutral
env
fig
b
respect
surprisingli
env
equal
sensit
neutral
two
mab
despit
homogen
sequenc
potent
neutral
patient
plasma
fig
mab
moder
sensit
neutral
two
env
fig
contrast
neutral
activ
detect
two
env
neutral
level
similar
observ
mab
fig
neutral
mab
fig
b
neutral
activ
env
clone
beyond
howev
undetect
mab
fig
b
provid
strong
evid
mab
could
repres
elicit
earli
infect
later
env
variant
develop
resist
mutat
protect
specif
ident
pattern
observ
purifi
mab
mean
sensit
env
ngml
respect
data
shown
env
beyond
neutral
mgml
either
purifi
mab
data
shown
resist
mab
involv
loss
gain
predict
glycan
addit
site
neutral
chimera
panel
mab
local
differ
sensit
domain
data
shown
examin
sequenc
nab
resist
env
reveal
one
differ
length
pattern
predict
glycosyl
site
sequenc
fig
howev
nab
resist
env
beyond
acquir
mutat
creat
potenti
glycosyl
site
posit
highlight
yellow
fig
furthermor
env
resist
lack
potenti
ngli
site
rel
env
highlight
yellow
fig
thu
figur
moder
neutral
breadth
plasma
heterolog
env
singl
plasma
sampl
evalu
neutral
activ
heterolog
env
acquir
acuteearli
subtyp
c
infect
six
subject
nab
titer
plasmaenv
combin
shown
vertic
axi
scale
data
point
repres
singl
plasmaenv
combin
arrow
indic
nab
titer
autolog
plasmaenv
combin
data
point
repres
heterolog
env
plasma
sampl
indic
point
plot
b
chimera
mutant
env
correspond
env
evalu
use
contemporan
plasma
pseudovirus
creat
express
env
envdefici
backbon
infect
tzmbl
cell
evalu
absenc
presenc
seriallydilut
patient
plasma
luciferas
quantit
measur
percent
viru
infect
rel
test
plasma
plot
vertic
axi
reciproc
plasma
dilut
plot
along
horizont
axi
scale
curv
repres
one
env
serial
plasma
dilut
error
bar
repres
standard
deviat
least
two
independ
experi
use
duplic
well
legend
list
parent
nab
resist
env
follow
chimer
mutant
env
creat
env
background
amino
acid
align
shown
indic
sequenc
differ
differ
env
c
e
color
text
correspond
curv
graph
region
contain
differ
shown
nab
resist
variant
util
distinct
escap
pathway
neutral
b
chimer
env
pseudovirus
gener
env
env
background
evalu
use
plasma
sampl
cell
luciferas
quantit
measur
percent
viru
infect
plot
reciproc
plasma
dilut
error
bar
repres
standard
deviat
least
two
independ
experi
use
duplic
well
panel
graph
indic
region
transfer
nab
resist
env
b
gray
box
white
box
c
amino
acid
align
region
env
hypothes
differ
array
potenti
glycan
addit
site
determin
pattern
sensit
two
mab
fig
show
natur
occur
pattern
predict
glycan
site
detect
earli
env
posit
site
interest
indic
red
blue
defin
effect
potenti
glycan
addit
site
sensit
two
mab
site
introduc
carri
neither
fig
mab
introduct
predict
glycan
site
result
dramat
increas
neutral
sensit
fig
contrast
introduct
predict
glycan
produc
moder
decreas
sensit
fig
introduct
predict
glycan
site
without
predict
glycan
site
result
strong
protect
mab
fig
thu
predict
glycosyl
site
potenti
track
protect
mab
summari
longitudin
env
glycan
site
see
tabl
result
also
demonstr
mab
target
epitop
recogn
distinct
structur
detect
env
resist
one
mab
unexpect
given
earli
time
high
sensit
env
patient
plasma
therefor
frequenc
predict
glycan
site
acuteearli
infect
investig
use
unclon
singl
genom
amplifi
sequenc
antibodyneg
sampl
sampl
antibodi
posit
see
tabl
sequenc
combin
five
clone
env
studi
highlight
plot
creat
use
hiv
databas
fig
fortyfour
sequenc
ident
throughout
contain
predict
glycan
addit
site
two
variant
includ
antibodi
posit
time
point
carri
ident
g
mutat
abrog
predict
glycan
addit
site
taken
togeth
observ
provid
strong
evid
founder
viru
like
env
carri
predict
glycan
site
mutat
aros
shortli
transmiss
circul
transient
previou
studi
demonstr
subtyp
c
infect
seroconvertor
mount
robust
nab
respons
autolog
virus
earli
stage
infect
extend
find
demonstr
cycl
viral
escap
occur
despit
potent
nab
cycl
involv
multipl
mechan
region
env
subject
earli
nab
escap
requir
amino
acid
substitut
independ
glycosyl
possibl
chang
directli
alter
epitop
region
may
access
nab
env
trimer
howev
attempt
remov
nab
activ
peptid
unsuccess
env
chimera
unrel
env
engin
carri
sequenc
lack
biolog
activ
data
shown
thu
neither
approach
allow
definit
identif
epitop
latter
suggest
domain
proxim
region
like
evolv
concert
adjac
region
protein
anoth
possibl
earli
chang
creat
conform
chang
protect
distinct
target
ntermin
region
shown
contain
contact
site
mab
escap
mutat
could
therefor
influenc
exposur
epitop
bind
site
two
altern
epitop
mutat
mask
mutual
exclus
conceiv
chang
could
protect
one
antibodi
specif
clearli
case
singl
amino
acid
chang
creat
potenti
glycan
addit
site
result
resist
two
distinct
mab
later
time
point
subject
flexibl
env
structur
provid
altern
mutat
pathway
resist
neutral
escap
pathway
oscil
chang
local
outer
domain
conform
mask
strategi
requir
interact
spatial
separ
env
subregion
fig
b
major
determin
also
one
nab
resist
env
see
fig
neutral
curv
howev
env
two
time
point
independ
confer
resist
appear
requir
contribut
nab
resist
env
three
time
point
region
ectodomain
requir
resist
map
one
env
demonstr
domain
contribut
larg
part
phenotyp
domain
context
interestingli
domain
subject
contain
chang
predict
glycosyl
pattern
rel
env
other
sequenc
chang
would
alter
origin
glycosyl
pattern
fig
novel
find
nab
resist
env
util
distinct
env
subregion
block
nab
pool
provid
strike
exampl
converg
intrapati
evolut
earli
infect
one
pathway
heavili
depend
domain
exhibit
codepend
domain
two
env
contain
predict
glycosyl
shift
fig
green
white
sphere
differ
primari
amino
acid
sequenc
fig
rais
possibl
env
contain
mutat
directli
confer
epitop
escap
env
retain
target
escap
indirect
mechan
addit
region
flank
proxim
bind
site
could
therefor
alter
exposur
propos
chang
context
shiv
infect
thu
examin
singl
subject
great
detail
uncov
remark
flexibl
pathway
viral
escap
earli
infect
result
highlight
plastic
env
hypervari
domain
coupl
complex
conform
interact
could
provid
numer
option
escap
contrast
subject
nab
escap
driven
predominantli
chang
domain
fig
b
prefer
potenti
glycan
shift
becam
evid
spatial
represent
env
four
predict
glycosyl
site
chang
observ
alon
fig
green
white
sphere
env
import
escap
illustr
demonstr
two
predict
glycan
site
one
one
influenc
neutral
two
mab
deriv
subject
thu
studi
first
identifi
specif
mutat
confer
autolog
nab
resist
singl
antibodi
level
made
possibl
sever
observ
appar
polyclon
plasma
first
singl
substitut
confer
resist
multipl
antibodi
specif
within
individu
formal
show
glycosyl
substitut
site
respons
resist
mab
strong
evid
studi
support
case
second
differ
pathway
escap
also
oper
singl
antibodi
level
resist
could
achiev
either
addit
predict
glycan
site
loss
predict
glycan
site
interestingli
modif
retain
subsequ
escap
variant
suggest
could
advantag
term
escap
mainten
replic
fit
third
mutat
confer
escap
multipl
monoclon
antibodi
specif
necessarili
confer
escap
entir
polyclon
nab
milieu
plasma
modif
env
confer
complet
resist
mg
ml
partial
escap
patient
plasma
fig
data
shown
find
suggest
escap
determin
map
plasma
reflect
domin
nab
specif
present
rel
high
concentr
abl
inhibit
viru
infect
greater
dilut
assay
lower
titer
nab
specif
could
also
drive
escap
mutat
rel
contribut
differ
antibodi
specif
plasma
undoubtedli
vari
among
subject
potenti
even
within
subject
time
result
need
custom
escap
pathway
driven
domin
nab
respons
thu
deriv
complet
pictur
autolog
nab
escap
necessari
recov
character
individu
mab
differ
specif
done
recent
other
dissect
b
cell
respons
subject
neutral
breadth
studi
demonstr
subtyp
c
env
uniqu
equip
respond
current
immun
respons
individu
host
adjust
pathway
escap
mutat
confer
resist
appear
first
eight
month
infect
howev
recov
memori
b
cell
circul
month
later
possibl
determin
whether
relat
b
cell
circul
earli
infect
chang
confer
resist
present
time
subject
seroposit
transient
mutat
occur
respons
immun
pressur
antibodi
must
present
within
day
calcul
time
infect
inde
observ
low
level
neutral
activ
plasma
env
data
shown
consist
concept
other
observ
earli
antibodi
respons
within
first
day
infect
lack
neutral
activ
direct
predominantli
find
rais
possibl
viral
neutral
escap
could
occur
earlier
previous
thought
individu
mab
deriv
b
cell
earli
infect
blue
backbon
gener
homolog
model
env
sequenc
onto
structur
model
loop
describ
previous
red
indic
amino
acid
chang
rel
env
sequenc
sphere
indic
chang
potenti
nlink
glycosyl
site
green
loss
white
gain
test
founder
viru
env
may
requir
detect
initi
nab
activ
therefor
import
determin
whether
nab
activ
viral
escap
present
subtyp
c
infect
subject
earli
time
point
well
whether
earli
escap
mutat
associ
decreas
viral
fit
blue
backbon
gener
homolog
model
env
sequenc
onto
structur
model
loop
describ
previous
red
indic
amino
acid
chang
rel
env
sequenc
sphere
indic
chang
potenti
nlink
glycosyl
site
green
loss
white
gain
spatial
properti
escap
pathway
importantli
studi
sequenc
chang
link
directli
nab
escap
exampl
one
first
sequenc
chang
present
env
substitut
first
posit
helix
howev
chang
alter
nab
sensit
contemporan
plasma
introduc
env
revers
mutat
escap
variant
also
increas
sensit
autolog
nab
murphi
et
al
prepar
nab
escap
variant
also
exhibit
variat
helix
begin
region
appear
contribut
independ
nab
escap
find
support
target
directli
nab
instanc
despit
ongo
sequenc
evolut
helix
link
autolog
heterolog
nab
sensit
subtyp
c
env
zambia
south
africa
india
group
other
howev
exact
role
nab
sensit
escap
remain
undetermin
specul
helix
play
ancillari
role
nab
escap
perhap
particip
mainten
tertiari
structur
outer
domain
quaternari
structur
trimer
find
present
support
earlier
find
rule
possibl
helix
target
nab
instanc
low
titer
nab
specif
studi
ongo
laboratori
precis
defin
role
chang
helix
context
autolog
nab
addit
helix
sequenc
variat
observ
region
outer
domain
env
fig
b
respect
howev
region
strongest
effect
nab
resist
major
determin
companion
studi
four
subtyp
c
infect
seroconvertor
previou
studi
subtyp
c
chronic
infect
subject
report
consist
find
commonli
involv
nab
escap
vari
degre
moor
et
al
press
importantli
combin
biolog
result
spatial
analysi
two
subject
demonstr
perpetu
flexibl
domain
provid
formid
defens
nab
could
due
part
abil
simultan
mask
multipl
epitop
limit
chang
may
also
involv
direct
escap
although
studi
conduct
small
number
subject
still
benefici
work
toward
develop
mechanist
model
explain
underli
complex
escap
pathway
within
subject
result
present
provid
basi
endeavor
first
escap
pathway
observ
appear
defin
nab
resist
combin
direct
indirect
mechan
direct
epitop
chang
may
suffici
set
limit
antibodi
specif
earli
phase
infect
indirect
mask
cooper
mechan
may
requir
later
multipl
antibodi
specif
circul
howev
import
expand
confirm
studi
character
nab
escap
addit
subject
frequenc
time
underli
basi
converg
escap
pathway
within
subject
requir
investig
signific
region
subtyp
c
env
appear
posit
select
contribut
directli
escap
plasma
nab
lastli
import
determin
differ
escap
pathway
share
common
conform
basi
point
specif
region
env
incorpor
exclud
vaccin
immunogen
inform
consent
human
subject
protocol
approv
emori
univers
institut
review
board
figur
sequenc
variat
occur
similar
region
env
represent
sequenc
variat
time
shown
panel
b
respect
backbon
gener
homolog
model
env
sequenc
onto
structur
model
loop
describ
previous
blue
green
red
indic
degre
sequenc
conserv
high
low
within
align
univers
zambia
school
medicin
research
ethic
committe
written
inform
consent
obtain
human
subject
zambia
emori
hiv
research
project
zehrp
establish
lusaka
provid
voluntari
test
counsel
longterm
monitor
health
care
cohabit
heterosexu
coupl
detail
cohort
describ
elsewher
briefli
hivdiscord
coupl
enrol
studi
transmiss
monitor
seroconvers
neg
partner
threemonth
interv
time
particip
also
receiv
prevent
counsel
condom
bank
plasma
sampl
seroneg
partner
test
antigen
elisa
identifi
individu
acut
infect
two
subtyp
c
infect
seroconvertor
studi
particip
cohort
identifi
antigen
posit
seroposit
rapid
test
western
blot
describ
plasma
viral
load
determin
use
roch
amplicor
assay
none
subject
receiv
antiretrovir
therapi
evalu
period
condit
singl
genom
pcr
amplif
fulllength
plu
rev
vpu
partial
nef
code
sequenc
genom
dna
uncultur
peripher
blood
mononuclear
cell
cdna
plasma
describ
previous
viral
env
amplicon
direct
ta
clone
cmvdriven
express
plasmid
screen
biolog
function
pseudovirus
follow
cotransfect
envdefici
subtyp
b
provir
plasmid
cell
seventytwo
hour
later
supernat
collect
use
infect
tzmbl
cell
hour
postinfect
bgal
stain
perform
well
score
posit
neg
blue
foci
dna
sequenc
env
gene
carri
lone
star
lab
inc
houston
tx
util
abi
prism
h
autom
dna
sequenc
big
dye
tm
termin
readi
reaction
cycl
sequenc
kit
nucleotid
sequenc
edit
assembl
use
sequench
translat
use
seal
nucleotid
amino
acid
align
creat
use
clustal
w
neighbor
join
phylogenet
tree
gener
clustal
w
use
gapstrip
nucleotid
sequenc
complet
env
gene
reliabl
branch
order
assess
bootstrap
analysi
use
replic
tree
visual
use
nj
plot
align
sequenc
import
highlight
tool
analyz
viral
divers
http
wwwhivlanlgovcont
sequencehighlighthighlighterhtml
sequenc
deposit
genbank
access
number
patient
plasma
sampl
evalu
neutral
antibodi
activ
virion
pseudotyp
autolog
patientderiv
viral
env
use
singl
round
report
assay
describ
previous
briefli
tzmbl
cell
plate
cultur
overnight
two
thousand
infecti
unit
pseudoviru
combin
fivefold
dilut
heatinactiv
patient
plasma
incub
hour
normal
heatinactiv
human
plasma
ad
necessari
maintain
constant
overal
concentr
virusab
mixtur
ad
cell
two
day
cell
lyse
luciferas
activ
well
measur
use
luminomet
background
luminesc
determin
uninfect
well
subtract
experiment
well
percent
infect
calcul
divid
number
luciferas
unit
plasma
dilut
valu
well
contain
test
plasma
dilut
patient
plasma
inhibit
viru
infect
titer
determin
use
microsoft
excel
mac
growth
function
experi
perform
independ
least
twice
duplic
well
chimer
env
construct
use
domain
exchang
strategi
describ
previous
primer
sequenc
locat
shown
pcr
screen
perform
identifi
transform
fragment
ligat
togeth
correct
orient
use
forward
primer
enva
revers
primer
use
amplifi
exchang
domain
coloni
posit
pcr
screen
inocul
lbampicillin
broth
overnight
cultur
plasmid
prepar
use
qiaprep
spin
miniprep
kit
env
chimera
screen
biolog
function
describ
chimera
produc
function
env
pseudotyp
plasmid
retransfect
cell
larger
scale
produc
work
pseudotyp
viru
stock
transfect
supernat
collect
hour
posttransfect
clarifi
low
speed
centrifug
aliquot
ml
less
portion
store
titer
pseudoviru
stock
determin
infect
cell
serial
dilut
viru
describ
previous
env
chimera
confirm
nucleotid
sequenc
entir
env
gene
env
backbon
minu
target
domain
vector
sequenc
pcr
amplifi
use
primer
anneal
conserv
region
adjac
target
domain
primer
primer
amplifi
away
target
domain
phosphat
group
pho
ad
primer
set
synthesi
facilit
ligat
target
domain
amplicon
primer
sequenc
locat
follow
subject
domain
backbon
forward
primer
nt
revers
primer
nt
domain
backbon
forward
primer
nt
revers
primer
nt
domain
backbon
forward
primer
nt
revers
primer
nt
ectodomain
backbon
forward
primer
nt
revers
primer
nt
domain
backbon
forward
primer
nt
revers
primer
nt
pcr
amplif
condit
env
backbon
cycl
min
cycl
min
optim
anneal
temperatur
determin
primer
set
min
cycl
min
storag
amplif
condit
target
domain
except
extens
time
reduc
ml
pcr
mixtur
contain
ng
primer
ng
plasmid
templat
mm
mgcl
mm
deoxynucleosid
triphosph
reaction
buffer
pfuultra
ii
dna
polymeras
stratagen
use
gener
bluntend
pcr
amplicon
digest
dpni
remov
contamin
templat
dna
gel
purifi
agaros
gel
use
qiaquick
gel
extract
kit
qiagen
prior
ligat
target
domain
dna
fragment
ligat
purifi
env
backbon
produc
chimera
use
dna
ligas
uml
roch
overnight
ligat
reaction
mixtur
usual
onethird
volum
transform
maximumeffici
ultracompet
cell
cfumg
dna
stratagen
dna
volum
exceed
cell
volum
entir
transform
plate
onto
lbampicillin
agar
plate
gener
result
coloni
per
ligat
reaction
investig
whether
individu
amino
acid
sequenc
differ
contribut
neutral
resist
phenotyp
pcrbase
sitedirect
mutagenesi
use
introduc
amino
acid
chang
describ
previous
briefli
set
primer
use
either
wildtyp
mutat
sequenc
primer
sequenc
locat
shown
substitut
nucleotid
underlin
mutant
confirm
sequenc
entir
env
gene
pcr
amplif
condit
cycl
min
cycl
min
cycl
min
pcr
mixtur
contain
ng
primer
ng
plasmid
templat
mm
deoxynucleosid
triphosph
buffer
pfuultra
hf
dna
polymeras
stratagen
use
amplicon
digest
dpni
remov
contamin
templat
dna
ml
transform
maximumeffici
ultracompet
cell
cfumg
dna
stratagen
half
transform
plate
onto
lbampicillin
agar
plate
gener
result
coloni
per
reaction
mutant
confirm
sequenc
entir
env
gene
human
b
cell
hybridoma
gener
viabl
frozen
pbmc
sampl
subject
base
protocol
ebv
immort
peripher
blood
b
cell
describ
previous
protocol
includ
immort
preselect
memori
b
cell
popul
cultur
medium
supplement
immunostimulatori
cpg
sequenc
irradi
allogen
pbmc
describ
ebvtransform
b
cell
cultur
screen
mab
neutral
env
bound
envelop
glycoprotein
elisa
method
use
screen
neutral
mab
modif
tzmbl
luciferas
report
cell
assay
origin
develop
wei
et
al
ebvtransform
b
cell
hybridoma
neutral
activ
clone
presenc
cpg
irradi
pbmc
cultur
supernat
collect
two
hybridoma
use
neutral
studi
map
target
escap
figur
phylogenet
tree
longitudin
env
neighborjoin
tree
gener
use
clustal
w
v
figur
amino
acid
sequenc
align
env
three
nab
sensit
env
six
nab
resist
env
subsequ
time
point
select
studi
env
env
clone
indic
time
point
month
sourc
pb
pbmc
dna
pl
plasma
clone
number
sequenc
shown
refer
amino
acid
differ
indic
letter
delet
residu
indic
dot
domain
transfer
env
creat
chimera
follow
blue
gray
green
nt
blue
nt
green
nt
major
env
domain
indic
region
helix
underlin
two
potenti
nlink
glycan
addit
site
interest
nx
nxt
x
residu
prolin
highlight
yellow
found
mb
pdf
figur
amino
acid
sequenc
align
env
two
nab
sensit
env
ten
nab
resist
env
subsequ
time
point
select
studi
env
env
clone
indic
time
point
month
sourc
pb
pbmc
dna
pl
plasma
clone
number
sequenc
shown
refer
env
amino
acid
differ
indic
letter
delet
residu
indic
dot
domain
transfer
env
creat
chimera
follow
blue
gray
green
nt
blue
nt
green
nt
ectodomain
yellow
nt
found
mb
pdf
figur
major
determin
nab
resist
env
chang
time
neutral
parent
chimer
env
pseudovirus
evalu
use
longitudin
plasma
sampl
indic
panel
plasma
sampl
contemporan
nab
resist
env
neutral
sensit
evalu
cell
use
luciferas
quantit
measur
percent
viru
infect
plot
reciproc
reciproc
plasma
dilut
error
bar
repres
standard
deviat
least
two
independ
experi
use
duplic
well
chimera
creat
background
red
line
legend
parent
env
clone
indic
follow
chimera
contain
indic
region
nab
resist
env
env
ecto
stand
ectodomain
found
mb
pdf
figur
major
determin
nab
resist
env
neutral
parent
chimer
env
pseudovirus
evalu
use
longitudin
plasma
sampl
indic
panel
plasma
sampl
contemporan
nab
resist
env
neutral
sensit
evalu
cell
use
luciferas
quantit
measur
percent
viru
infect
plot
reciproc
reciproc
plasma
dilut
error
bar
repres
standard
deviat
least
two
independ
experi
use
duplic
well
chimera
creat
background
red
line
legend
parent
env
clone
indic
follow
chimera
contain
indic
region
nab
resist
env
env
found
mb
pdf
figur
highlight
plot
show
nucleotid
mismatch
region
env
singl
genom
amplifi
unclon
sequenc
deriv
sampl
n
sampl
n
sequenc
singl
genom
amplifi
clone
env
sampl
n
subject
highlight
analysi
wwwhivlanlgov
tick
repres
mismatch
base
compar
master
sequenc
list
top
three
env
analyz
neutral
fig
box
red
pb
uncultur
pbmc
dna
pl
plasma
ga
mutat
diamond
locat
near
begin
sequenc
repres
loss
potenti
ngli
site
track
resist
found
mb
pdf
